MX2023008793A - Composiciones y métodos para el tratamiento de la enfermedad de injerto contra huésped. - Google Patents
Composiciones y métodos para el tratamiento de la enfermedad de injerto contra huésped.Info
- Publication number
- MX2023008793A MX2023008793A MX2023008793A MX2023008793A MX2023008793A MX 2023008793 A MX2023008793 A MX 2023008793A MX 2023008793 A MX2023008793 A MX 2023008793A MX 2023008793 A MX2023008793 A MX 2023008793A MX 2023008793 A MX2023008793 A MX 2023008793A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- host disease
- versus host
- graft versus
- compositions
- Prior art date
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title abstract 5
- 208000024908 graft versus host disease Diseases 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title 1
- 230000001154 acute effect Effects 0.000 abstract 2
- 229940007438 apraglutide Drugs 0.000 abstract 1
- 108700023633 apraglutide Proteins 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142905P | 2021-01-28 | 2021-01-28 | |
| US202163248074P | 2021-09-24 | 2021-09-24 | |
| PCT/US2022/014349 WO2022165204A1 (en) | 2021-01-28 | 2022-01-28 | Compositions and methods for the treatment of graft versus host disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008793A true MX2023008793A (es) | 2024-02-15 |
Family
ID=80461100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008793A MX2023008793A (es) | 2021-01-28 | 2022-01-28 | Composiciones y métodos para el tratamiento de la enfermedad de injerto contra huésped. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220233645A1 (https=) |
| EP (2) | EP4635509A1 (https=) |
| JP (1) | JP2024507324A (https=) |
| KR (1) | KR20230167019A (https=) |
| AU (1) | AU2022212119A1 (https=) |
| BR (1) | BR112023014978A2 (https=) |
| CA (1) | CA3206093A1 (https=) |
| ES (1) | ES3044110T3 (https=) |
| IL (1) | IL304675A (https=) |
| MX (1) | MX2023008793A (https=) |
| WO (1) | WO2022165204A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025208047A1 (en) * | 2024-03-28 | 2025-10-02 | Vectivbio Ag | Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8421271B2 (en) * | 2009-08-31 | 2013-04-16 | General Electric Company | Apparatus for transferring energy using onboard power electronics and method of manufacturing same |
| EP2314616A1 (en) | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
| EP3924369A1 (en) * | 2019-02-11 | 2021-12-22 | OPKO Biologics Ltd. | Long-acting glp-2 analogs |
| KR20230038187A (ko) | 2020-06-09 | 2023-03-17 | 벡티브바이오 에이지 | 아프라글루타이드의 제조, 제형화 및 투여 |
-
2022
- 2022-01-28 CA CA3206093A patent/CA3206093A1/en active Pending
- 2022-01-28 WO PCT/US2022/014349 patent/WO2022165204A1/en not_active Ceased
- 2022-01-28 ES ES22705498T patent/ES3044110T3/es active Active
- 2022-01-28 EP EP25186217.3A patent/EP4635509A1/en active Pending
- 2022-01-28 US US17/587,311 patent/US20220233645A1/en not_active Abandoned
- 2022-01-28 EP EP22705498.8A patent/EP4284410B1/en active Active
- 2022-01-28 MX MX2023008793A patent/MX2023008793A/es unknown
- 2022-01-28 KR KR1020237029222A patent/KR20230167019A/ko active Pending
- 2022-01-28 BR BR112023014978A patent/BR112023014978A2/pt unknown
- 2022-01-28 US US18/274,622 patent/US20240123036A1/en active Pending
- 2022-01-28 AU AU2022212119A patent/AU2022212119A1/en active Pending
- 2022-01-28 JP JP2023544229A patent/JP2024507324A/ja active Pending
-
2023
- 2023-07-24 IL IL304675A patent/IL304675A/en unknown
- 2023-10-13 US US18/486,390 patent/US20240285730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL304675A (en) | 2023-09-01 |
| JP2024507324A (ja) | 2024-02-19 |
| ES3044110T3 (en) | 2025-11-26 |
| AU2022212119A1 (en) | 2023-08-10 |
| AU2022212119A9 (en) | 2024-05-16 |
| EP4635509A1 (en) | 2025-10-22 |
| BR112023014978A2 (pt) | 2023-11-07 |
| EP4284410A1 (en) | 2023-12-06 |
| CA3206093A1 (en) | 2022-08-04 |
| EP4284410B1 (en) | 2025-07-02 |
| WO2022165204A1 (en) | 2022-08-04 |
| US20240123036A1 (en) | 2024-04-18 |
| US20220233645A1 (en) | 2022-07-28 |
| US20240285730A1 (en) | 2024-08-29 |
| KR20230167019A (ko) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012245A (es) | Compuestos, composiciones y metodos para el tratamiento del cancer. | |
| EP4233910A3 (en) | Methods of treatment of cholestatic diseases | |
| GEP20237519B (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| MX2025010397A (es) | Compuestos heterociclicos como inhibidores de la helicasa del sindrome de werner (wrn) | |
| MX395085B (es) | Tratamiento conjunto contra tipos de cancer hematologico. | |
| MX2022012471A (es) | Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas. | |
| WO2024006292A3 (en) | Methods of treating cancer | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2023004796A (es) | Compuestos, composiciones y metodos de uso para tratar fracturas oseas. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| WO2024163641A3 (en) | Formulations for treating cancer | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| EP4674415A3 (en) | Azaquinolines as inhibitors of cd38 | |
| PH12022551371A1 (en) | Macrocycles for use in treating disease | |
| MX2024003529A (es) | Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica. | |
| JOP20250313A1 (ar) | طرق علاج مرض الكلى المزمن باستخدام داباغليفلوزين | |
| MX2023008793A (es) | Composiciones y métodos para el tratamiento de la enfermedad de injerto contra huésped. | |
| MX2025004473A (es) | Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos | |
| EA201991395A1 (ru) | Новые композиции для лечения суставных нарушений | |
| MX2023006087A (es) | Formulaciones liofilizadas de tegavivint. | |
| ZA202106807B (en) | Antibodies having specificity for btn2 and uses thereof | |
| BR112020019624A8 (pt) | Método para tratar a hipoglicemia pós-prandial |